Aurisco(SH:605116)2021-04-19 16:00Financial Performance - The company's operating revenue for 2020 was CNY 721,440,229.88, representing a 24.04% increase compared to CNY 581,632,761.51 in 2019[25]. - The net profit attributable to shareholders for 2020 was CNY 157,227,222.39, a decrease of 15.53% from CNY 186,130,277.81 in 2019[25]. - The net profit after deducting non-recurring gains and losses was CNY 152,038,673.07, which is a 4.10% increase from CNY 146,047,573.83 in 2019[25]. - The net cash flow from operating activities for 2020 was CNY 214,481,140.46, up 19.22% from CNY 179,903,617.01 in 2019[25]. - The total assets at the end of 2020 were CNY 1,533,212,830.38, a 39.35% increase from CNY 1,100,247,816.67 at the end of 2019[25]. - The net assets attributable to shareholders at the end of 2020 were CNY 1,385,232,437.06, reflecting a 41.74% increase from CNY 977,283,198.52 at the end of 2019[25]. - The basic earnings per share for 2020 was CNY 0.42, down 19.23% from CNY 0.52 in 2019[26]. - The weighted average return on equity for 2020 was 14.28%, a decrease of 6.81 percentage points from 21.09% in 2019[26]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 1.20 per 10 shares, totaling RMB 48,120,000 based on a total share capital of 401,000,000 shares as of December 31, 2020[8]. - The cash dividend for 2019 was CNY 1.00 per 10 shares, amounting to CNY 36 million, which represented 19.34% of the net profit attributable to ordinary shareholders[147]. - The company aims to maintain a stable and continuous profit distribution policy, prioritizing cash dividends when conditions allow[145]. - The company’s profit distribution policy includes a minimum cash distribution of 20% of the available profit when there are no major investment plans[145]. Audit and Compliance - The company reported a standard unqualified audit opinion from Tianjian Accounting Firm for the fiscal year 2020[7]. - The company’s financial report has been confirmed as true, accurate, and complete by its management[5]. - The company has not violated any decision-making procedures regarding external guarantees[10]. - The company has not encountered any situations that would lead to a risk of suspension or termination of its listing[172]. - The company has not reported any significant accounting errors or changes in accounting policies that would impact its financial statements[170]. Research and Development - The company has a research and development team of 127 members, accounting for 13.53% of total employees, with 9 PhDs and 27 Master's degree holders[47]. - Research and development expenses totaled 47.35 million RMB, a 35% increase compared to the previous year, with five products successfully developed during the reporting period[56]. - The company submitted nine invention patents and received authorization for seven, totaling 15 valid patents by the end of the reporting period[56]. - The company has completed R&D for 5 products and has 16 products currently under development, with 127 R&D personnel including 9 PhDs[103]. - The company’s R&D investment amounted to 47.35 million RMB, accounting for 6.56% of operating revenue, with a year-on-year growth of 34.91%[108]. Market and Sales - The global pharmaceutical market is projected to exceed 1.5 trillion USD by 2023, with an annual growth rate of 4%-5%[40]. - In 2020, the revenue of China's pharmaceutical manufacturing industry was 2.48573 trillion RMB, with a year-on-year growth of 4.5%[41]. - The company has established a comprehensive sales system for APIs in the Americas, Europe, and Asia, with stable long-term partnerships with major pharmaceutical companies[49]. - The company’s major sales model is direct sales, primarily targeting formulation production enterprises, with a stable customer base established through long-term cooperation[111]. - The company’s overseas sales accounted for 96% of its main business revenue, highlighting its reliance on international markets[136]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[188]. - Wastewater discharge amounted to 71,000 tons, with actual COD emissions of 2.13 tons and ammonia nitrogen emissions of 0.11 tons[189]. - VOCs emissions from waste gas were recorded at 36.48 tons, with actual emissions of 0.999 tons[189]. - The company implemented a new RTO facility with a capacity of 20,000 m³/h for waste gas treatment, which is currently operational[194]. - The company has established a comprehensive environmental risk emergency mechanism and updated its emergency response plan for pollution incidents[198]. Corporate Governance - The company has committed to a lock-up period for major shareholders, lasting from September 21, 2020, to September 20, 2023, during which they cannot transfer or manage their shares[151]. - Shareholders are required to maintain a minimum selling price for their shares after the lock-up period, which cannot be lower than the adjusted issuance price[152]. - The company will publicly disclose any failure to adhere to lock-up commitments and will apologize to shareholders, with penalties including extending the lock-up period[157]. - The company has established long-term commitments regarding share transfers for its major shareholders, ensuring compliance with relevant regulations[154]. - The company has made commitments to ensure the accuracy and completeness of its IPO prospectus, taking legal responsibility for any misstatements[168].